In an in vivo IL-10-deficient mouse model, treatment with a pegylated leptin antagonist resulted in attenuation of the clinical colitis score, a reversal of colitis-associated pathogenesis suppression of systemic and mucosal inflammatory cytokine production, and an increase in mucosal Treg cells. Here, IL10 is linked to colitis.